Its receptor binding profile is fully characterized
Commercial availability would follow several months after approval, with widespread access likely beginning the following year
Three peptides, BPC-157, Thymosin Beta-4 (TB4), and its synthetic fragment TB-500, have generated significant interest in orthopedic and sports medicine for their potential to accelerate healing in tendons, ligaments, muscle, and bone
This systemic distribution means abdominal injections can support healing in shoulders, knees, or other distant locations
The glycine component contributes to extending this stability window by maintaining pH and preventing aggregation throughout the use period
All products are intended for in-vitro laboratory research only and are not for human or veterinary use